Apply now for the Proteona Oncology Challenge using ESCAPE™ Single Cell Proteogenomic Analysis
Innovative AI-driven genomic and proteomic analysis platform for improving cell therapy and immuno-oncology
SINGAPORE, 23 September 2019 - Proteona Pte. Ltd. has announced the launch of the first Proteona Oncology Challenge, co-sponsored by NovogeneAIT. All scientists and clinicians working to solve major clinical problems in oncology are welcomed to submit abstracts on how they would use ESCAPE™ RNA-Seq single cell proteogenomic analysis services. The winner will be awarded up to $50,000 worth of single cell analysis services from Proteona and NovogeneAIT, which includes ESCAPE™ RNA-Seq single cell data acquisition and access to Proteona’s AI analysis tools. Applications are open now at www.proteona.com/Challenge.html until 1st of November 2019.
Cancer treatment has progressed tremendously in the past decade. New approaches, such as immune-therapies, cell therapy, and personalized treatment, are becoming increasingly sophisticated and can potentially significantly improve clinical outcome. There is, however, more work needed. Clinicians and scientists are looking for better ways to address issues such as patient-to-patient variation, tumor heterogeneity, adverse effects, and the dearth of predictive biomarkers that can guide clinical decision making.
Multi-omic single cell analysis technology, combined with state-of-the-art data analysis tools, provides a powerful platform to elucidate the heterogeneity and complexity of biology. Enhanced Single Cell Analysis with Protein Expression and RNA Sequencing (ESCAPE™ RNA-Seq) is an innovative platform for obtaining protein and gene expression information from the same single cells. By clustering cells using well characterized protein surface markers, it adds essential cell phenotyping information to single cell RNA-seq data, therefore providing an in-depth understanding of cell populations and their functionalities. ESCAPE™ RNA-Seq enables deep characterization of clinical samples such as solid tumors, liquid tumors, and cell therapies, where heterogeneity is key to understanding the diverse cell populations and differential treatment response.
“There are a lot of great ideas out there on how single cell multi-omics analysis can solve real clinical problems. We want to help putting them into action. By providing some additional resources, we hope to help clinical researches to get over the initial technical and financial barrier, so that they can make full use of this powerful tool to make a difference in future cancer treatment,” says Dr. Andreas Schmidt, CEO of Proteona. “We will work very closely with the challenge winners and support them both on the wetlab and bioinformatics side.”
The full details on the grant challenge can be found at www.proteona.com/Challenge.html
For media queries, please contact:
Dr Andreas Schmidt
Proteona Pte. Ltd. is a new biomedical company based in Singapore, Germany, and the US that is pioneering the use of DNA barcoded antibodies to provide both proteomic and genomic information from the same single cells. Proteona is a spin-off from the National University of Singapore (NUS) and the Agency for Science, Technology and Research’s (A*STAR). The platform is a comprehensive sample to answer service that enables users to phenotype cells using standard protein markers and gain a deeper understanding of cell activity based upon their gene expression profiles.